BriefCase vs ContaCT
AI Verdict
Choose BriefCase if…
Choose BriefCase if your institution is already leveraging Aidoc's AI platform for critical medical imaging finding detection and requires an integrated, FDA-cleared solution to streamline communication and collaboration around those specific findings. It is ideal for ensuring timely sharing, automated follow-up, and comprehensive audit trails for urgent cases identified by Aidoc's AI.
View BriefCase →Choose ContaCT if…
Choose ContaCT if your primary goal is to accelerate the detection and treatment of time-sensitive conditions like stroke, pulmonary embolism, or hypertrophic cardiomyopathy through an AI-powered care coordination platform. This tool is best suited for health systems looking for real-time AI alerts, mobile access for specialists to view images, and secure communication to optimize workflows across multiple disease pathways.
View ContaCT →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
ContaCTBoth tools offer mobile access and integrate with existing hospital systems for streamlined workflows. However, Tool B (ContaCT) explicitly highlights a 'High-fidelity 3D web and mobile image viewer' which can significantly enhance the usability for specialists reviewing complex medical images, providing a slight edge in visual assessment capabilities.
Clinical Value
ContaCTWhile both are FDA-cleared and focus on critical findings, Tool B (ContaCT) lists specific AI-powered disease detections (LVO, ICH, HCM, PE, Aneurysm) and 'Guideline-based recommendations,' indicating a more direct and comprehensive impact on diagnostic and treatment pathways. Tool A (BriefCase) primarily focuses on communication of findings detected by the broader Aidoc platform, rather than direct disease detection capabilities within the tool itself.
Pricing & Value
TieBoth tools utilize enterprise or subscription-based pricing models that are customized based on factors like organization size, features, and implementation scope. Neither provides transparent pricing details, making it impossible to objectively compare their value propositions without specific quotes. Therefore, it is a tie in this dimension.
Enterprise Readiness
BriefCaseBoth tools demonstrate strong enterprise readiness with HIPAA compliance, BAA, FDA clearance, and cloud deployment, serving large hospital systems. However, Tool A (BriefCase) explicitly lists SOC2 and GDPR compliance, along with API availability, which provides a more comprehensive set of documented enterprise-grade features for security, data privacy, and integration capabilities.
Innovation
ContaCTTool B (ContaCT) positions itself as a 'pioneering AI-powered care coordination platform' with 'multiple FDA clearances, including the initial Viz.AI Contact application for stroke,' suggesting early market leadership and continuous innovation in disease detection. Its features like 'Automated chart summarization' and 'Guideline-based recommendations' demonstrate a broader application of AI beyond just communication, indicating a higher degree of innovative functionality.
Support & Docs
TieBased on available information, both Aidoc and Viz.AI, as leading enterprise healthcare AI providers, offer comprehensive customer support and training. Their websites indicate dedicated customer success teams and 24/7 support. Without more specific comparative details on the quality or depth of their documentation or support channels, it is difficult to distinguish a winner.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | BriefCase | ContaCT |
|---|---|---|
| Name | BriefCase | ContaCT |
| Company | Aidoc Medical | Viz.AI |
| Description | Aidoc's BriefCase is an FDA-cleared AI-powered communication and collaboration solution integrated into the Aidoc platform, designed to streamline the sharing of critical medical imaging findings among care teams. | Viz.ai is a pioneering AI-powered care coordination platform that accelerates disease detection and streamlines clinical workflows. With multiple FDA clearances, including the initial Viz.AI Contact application for stroke, it helps ensure patients receive timely treatment across over 1,700 hospitals globally. |
| Mobile App | both | Not specified |
| Key Features | AI-driven critical finding detection (via Aidoc platform), Secure, real-time communication of findings, Customizable communication protocols, Automated follow-up tracking and reminders, Seamless integration with PACS, RIS, and EHR systems, Comprehensive audit trails for all communications, Prioritization of urgent cases for immediate attention, Mobile access for care team collaboration | AI-powered disease detection (LVO, ICH, HCM, PE, Aneurysm), Real-time AI-powered alerts and notifications, Mobile application for specialists to view images and communicate, Secure, HIPAA-compliant group communication messaging, Integration with PACS and EHR systems, High-fidelity 3D web and mobile image viewer, Automated chart summarization, Guideline-based recommendations |
| Target Size | Large hospitals and health systems | Not specified |
| Customer Count | 500+ hospitals globally | over 1,700 hospitals globally |
Videos
Demos, reviews, and walkthroughs featuring BriefCase and ContaCT.